Improved Cancer DetectionAt the Point of Care.
Promaxo's MRI-Guided targeted transperineal biopsy detects cancer that standard TRUS biopsy misses — with fewer cores, no transrectal route, and up to 7x higher reimbursement. Thousands of patients treated across a global footprint of deployed systems.
Almost 2x improvement
vs standard of care.
Every Advantage.
In One Procedure.
MRI-Guided transperineal biopsy delivers what urologists and patients both want — higher detection, fewer cores, safer access, and a procedure that fits inside the practice workflow.
Three Targeted Cores
MRI visualization targets the lesion directly, reducing unnecessary sampling while improving confidence in each core.
Transperineal Route
The transperineal approach avoids the rectal wall, supporting a cleaner biopsy pathway with fewer infection concerns.
Live MR Guidance
Live MR imaging confirms needle position and sample location during the procedure, without fusion lag or cognitive registration.
Point-of-Care MRI
Single-sided MRI fits inside the urology workflow, helping practices deliver MRI guidance capabilities to the point of care.
Promaxo's platform technology has allowed me to identify cancer that a standard TRUS biopsy would have otherwise missed.
Designed for You.
Open form factor. Quiet operation. No claustrophobia. A familiar clinical setting where patients feel comfortable — not an intimidating MRI suite.
No transrectal route
Transperineal access eliminates the 7% infection risk entirely.
Open, quiet MRI
No claustrophobia. No loud noises. Comfortable patient experience.
Streamlined procedure
Imaging and biopsy in one visit at the familiar urology practice.
Faster recovery
Minimally invasive with no hospitalization required.
Up to 7x Reimbursement.
See it in Action.
See how providers have used Biopsy CPT codes (55713, 55714, & 55715 codes) and MRI imaging CPT codes.